GlassScriptPhysician profile
Russell Brunet
NPI 1790997690
$13,397.54
in general payments reported to CMS, 2019-2025
54 companies · $1,508 in 2025
The $1,508 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,000 · 2020: $535 · 2021: $1,331 · 2022: $2,360 · 2023: $3,377 · 2024: $2,285 · 2025: $1,508.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,171.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,170.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,936.80 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Amgen INC. | $1,394.40 | 2019-2025 | Repatha, Evenity, Otezla |
| Lilly USA, LLC | $1,010.32 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $967.34 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $945.17 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $748.65 | 2019-2025 | |
| Glaxosmithkline, LLC. | $676.55 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Allergan, INC. | $569.93 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $522.54 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $443.86 | 2019-2024 | Jardiance |
| Sanofi-Aventis U.S. LLC | $299.17 | 2019-2025 | |
| Abbott Laboratories | $291.60 | 2022-2023 | Freestyle Libre 3 |
| Idorsia Pharmaceuticals US INC | $257.59 | 2023 | Quviviq |
| Janssen Pharmaceuticals, INC | $250.98 | 2019-2022 | |
| Mylan Specialty L.P. | $236.72 | 2021-2024 | Yupelri |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Russell Brunet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.